Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations

Brian Haymart; Geoffrey D Barnes; Xiaowen Kong; Mona Ali; Eva Kline-Rogers; Deborah DeCamillo; Scott Kaatz

doi:10.1001/jamanetworkopen.2022.22089

Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations

JAMA Netw Open. 2022 Jul 1;5(7):e2222089. doi: 10.1001/jamanetworkopen.2022.22089.

Authors

Brian Haymart¹, Geoffrey D Barnes¹, Xiaowen Kong¹, Mona Ali², Eva Kline-Rogers¹, Deborah DeCamillo¹, Scott Kaatz³

Affiliations

¹ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor.
² Department of Heart and Vascular Services, Beaumont Hospital, Royal Oak, Michigan.
³ Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan.

Abstract

This cohort study evaluates stroke and major bleeding rates before and after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants* / adverse effects
Humans
Rivaroxaban / therapeutic use
Warfarin* / therapeutic use

Substances

Anticoagulants
Warfarin
Rivaroxaban